Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
EARLY_PHASE1
30
about 4.8 years
18+
1 site in PA
What this study is about
Researchers are testing a treatment with pembrolizumab and lenvatinib before surgery to see if it affects the immune system's response to kidney cancer. The trial will last about 1734 days, involving approximately 30 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Pembrolizumab infusion
- 2.Take Lenvatinib tablet
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lenvatinib, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Capsule), infusion
Secondary: Frequency of surgical delays (>7 days from initially planned operative date), prolonged operative hospitalization (>7 days), or infections (within 30 days of nephrectomy).
Oncology